A repurposed anti-cancer drug, Cilengitide, was found to reduce kidney scarring and slow disease progression in preclinical ...

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

In all of last year, the FDA handed out only four new exemptions, including one in February 2024 that covered a pediatric cartridge for continuous renal replacement therapy developed by SeaStar ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Ind ...

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a ...